Quest Diagnostics (NYSE:DGX) Updates FY 2025 Earnings Guidance

Quest Diagnostics (NYSE:DGX) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 9.550-9.800 for the period, compared to the consensus EPS estimate of 9.720. The company issued revenue guidance of $10.7 billion-$10.9 billion, compared to the consensus revenue estimate of $10.7 billion.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Jefferies Financial Group restated a “buy” rating and set a $185.00 price target (up from $175.00) on shares of Quest Diagnostics in a report on Tuesday, December 10th. Citigroup increased their price target on Quest Diagnostics from $165.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Leerink Partners raised Quest Diagnostics from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $169.00 to $174.00 in a research report on Monday, January 6th. Baird R W raised Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 23rd. Finally, UBS Group lifted their target price on Quest Diagnostics from $165.00 to $166.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Quest Diagnostics presently has a consensus rating of “Moderate Buy” and an average price target of $172.69.

Quest Diagnostics Trading Up 0.2 %

Shares of DGX opened at $164.47 on Friday. The business’s 50-day moving average price is $155.42 and its 200-day moving average price is $153.43. The company has a quick ratio of 1.17, a current ratio of 1.25 and a debt-to-equity ratio of 0.83. Quest Diagnostics has a twelve month low of $123.04 and a twelve month high of $167.08. The stock has a market cap of $18.36 billion, a PE ratio of 22.10, a P/E/G ratio of 2.43 and a beta of 0.90.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Thursday, January 30th. The medical research company reported $2.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.04. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.25%. On average, equities analysts forecast that Quest Diagnostics will post 8.9 EPS for the current fiscal year.

Quest Diagnostics Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 21st. Shareholders of record on Monday, April 7th will be issued a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 1.95%. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.75. Quest Diagnostics’s dividend payout ratio (DPR) is presently 40.32%.

Insider Transactions at Quest Diagnostics

In other Quest Diagnostics news, CAO Michael J. Deppe sold 18,755 shares of Quest Diagnostics stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $154.05, for a total transaction of $2,889,207.75. Following the transaction, the chief accounting officer now directly owns 34,941 shares of the company’s stock, valued at approximately $5,382,661.05. This trade represents a 34.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.79% of the stock is owned by insiders.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.